MARKET

DXCM

DXCM

DexCom
NASDAQ

Real-time Quotes | Nasdaq Last Sale

397.78
+2.31
+0.58%
After Hours: 397.78 0 0.00% 16:50 02/26 EST
OPEN
396.79
PREV CLOSE
395.47
HIGH
402.49
LOW
386.12
VOLUME
666.70K
TURNOVER
--
52 WEEK HIGH
456.23
52 WEEK LOW
182.07
MARKET CAP
38.26B
P/E (TTM)
79.69
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Diabetes management device system market is expected to grow at a CAGR of around 5.4% from 2019 to 2026
pune, India, Fri, 26 Feb 2021 00:20:46 / Comserve Inc. / -- Acumen Research and Consulting, Recently Published Report on titled "Diabetes Management Device...
Comserve · 16h ago
Looking For The Best Software Stocks To Buy In February? 3 Reporting Earnings Today
Feb 24, 2021 (StockMarket.com via COMTEX) -- Are These The Top Software Stocks To Buy Today? Software stocks have seen a meteoric rise in valuation recently....
StockMarket.com · 2d ago
Are These The Best Health Care Stocks To Watch This Week? 3 In Focus
Feb 24, 2021 (StockMarket.com via COMTEX) -- Do You Have These Top Health Care Stocks On Your Watchlist? In the stock market today, health care stocks are in...
StockMarket.com · 2d ago
Biggest Gains in Social Responsibility in the Management Top 250
DexCom, Regency Centers and Maxim Integrated Products head the list.
marketwatch.com · 2d ago
DJ Biggest Gains in Social Responsibility in the Management Top 250 -- Journal Report
Dow Jones · 2d ago
Diabetes Care Devices Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 23, 2021 (Market Insight Reports) -- The Global Diabetes Care Devices Market is estimated to value over USD 5.1 billion by 2027 end at a CAGR of over 16%...
Market Insight Reports · 3d ago
Steve Mandel's Lone Pine Reports 4th-Quarter Portfolio
GuruFocus News · 4d ago
Connected Medical Devices Market Research Report by Type, by Device, by Product, by End-User, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19
New York, Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DXCM. Analyze the recent business situations of DexCom through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DXCM stock price target is 467.56 with a high estimate of 540.00 and a low estimate of 350.00.
EPS
Institutional Holdings
Institutions: 1.02K
Institutional Holdings: 99.59M
% Owned: 103.55%
Shares Outstanding: 96.18M
TypeInstitutionsShares
Increased
278
9.04M
New
201
-1.36M
Decreased
238
8.82M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.63%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Sayer
Chief Financial Officer/Chief Operating Officer
Quentin Blackford
Executive Vice President/Chief Technology Officer
Jake Leach
Executive Vice President
Donald Abbey
Executive Vice President
Andrew Balo
Executive Vice President
Patrick Murphy
Executive Vice President
Steven Pacelli
Senior Vice President - Finance/Chief Accounting Officer
Jereme Sylvain
Senior Vice President
Jeffrey Moy
Senior Vice President
Shelly Selvaraj
Lead Director/Independent Director
Mark Foletta
Independent Director
Steven Altman
Independent Director
Nicholas Augustinos
Independent Director
Richard Collins
Independent Director
Karen Dahut
Independent Director
Bridgette Heller
Independent Director
Barbara Kahn
Independent Director
Kyle Malady
Independent Director
Jay Skyler
Independent Director
Eric Topol
  • Dividends
  • Splits
  • Insider Activity
No Data
About DXCM
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Webull offers kinds of DexCom, Inc. stock information, including NASDAQ:DXCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DXCM stock methods without spending real money on the virtual paper trading platform.